Name:
Analysis of patients’ side effects and quality of life in the ADAURA study
Description:
Analysis of patients’ side effects and quality of life in the ADAURA study
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/5c91211c-b8d6-47d0-bda0-a6502d8ce46e/videoscrubberimages/Scrubber_57.jpg
Duration:
T00H02M08S
Embed URL:
https://stream.cadmore.media/player/5c91211c-b8d6-47d0-bda0-a6502d8ce46e
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/5c91211c-b8d6-47d0-bda0-a6502d8ce46e/VJBM-2023-0012 final approved version.mp4?sv=2019-02-02&sr=c&sig=wcMR6gUsllvsmlw1gHd1qTEfPtaCUTCaDkQLTZrRsHQ%3D&st=2024-11-21T09%3A24%3A55Z&se=2024-11-21T11%3A29%3A55Z&sp=r
Upload Date:
2024-08-15T00:00:00.0000000
Transcript:
Language: EN.
Segment:0 .
Osimertinib is a drug that blocks the mutated form of a protein called EGFR on cancer cells and is the recommended treatment for patients with advanced or early-stage non-small cell lung cancer with certain types of EGFR mutations.
The phase III ADAURA study assessed osimertinib treatment for patients with stage IB to IIIA non-small cell lung cancer with two common types of EGFR mutations known as EGFR exon 19 deletion or L858R after surgery to remove the tumour (and chemotherapy, for those eligible). Participants received osimertinib or placebo for up to 3 years, unless the cancer came back, or treatment was stopped for other reasons, such as side effects. The study assessed how well osimertinib treatment worked and its side effects.
Osimertinib lengthened the time patients remained alive and cancer-free, compared with placebo. Most side effects were mild or moderate. The most common side effects with osimertinib were diarrhea, nail changes, dry skin, and itchy skin. Most patients did not need to reduce the amount of drug given, or pause, or stop their treatment due to side effects. Most of the patients’ self-assessment of their quality of life remained consistent over the treatment period. The ADAURA data show that osimertinib following surgery can prolong the time patients remain alive and cancer-free; treatment side effects were manageable, and the patient’s quality of life was maintained.